MarketPulse

menin inhibitor

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Biomea Fusion Slashes Q1 Loss 58% as Icovamenib Shows Promise in Diabetes Trial

Biomea Fusion cuts Q1 net loss 58% to $12.4M while advancing diabetes and obesity trials with positive early efficacy signals.
BMEAclinical trialsType 1 diabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biomea Fusion to Present Icovamenib Diabetes Data at ADA Conference

Biomea Fusion selected for three late-breaking poster presentations on icovamenib at ADA 86th Scientific Sessions in June 2026, showcasing Phase 2 trial results.
BMEAPhase 2 clinical trialType 1 diabetes
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kyowa Kirin, Kura Oncology Launch Japanese Phase 2 Trial for FDA-Approved Ziftomenib

Kyowa Kirin and Kura Oncology begin Japanese Phase 2 registrational trial for ziftomenib in relapsed/refractory NPM1-mutated AML, following FDA approval.
KURAPhase 2 clinical trialhematologic malignancies
GlobeNewswire Inc.GlobeNewswire Inc.··Biomea Fusion, Inc.

Biomea Fusion's Diabetes Drug Shows Durable Benefits Nine Months Post-Dose

Biomea Fusion presents positive Phase II data for icovamenib in type 2 diabetes, showing durable 1.2% HbA1c reduction nine months after dosing with favorable safety profile.
BMEAobesityType 2 diabetes